acebutolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 40 37517-30-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • IL-17803A
  • acebutolol HCl
  • acebutolol
  • acebutolol hydrochloride
  • (RS)-Acebutolol
  • (+/-)-Acebutolol
  • dl-Acebutolol
A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.
  • Molecular weight: 336.43
  • Formula: C18H28N2O4
  • CLOGP: 1.71
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 87.66
  • ALOGS: -3.29
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 46.09 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 37 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.74 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1984 FDA PROMIUS PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Orthostatic hypotension 1355.03 38.05 397 8350 35763 63444512
Sedation complication 1332.67 38.05 321 8426 13501 63466774
Creatinine renal clearance decreased 1284.91 38.05 322 8425 15986 63464289
Cognitive disorder 1277.73 38.05 420 8327 55395 63424880
Sedation 1253.69 38.05 380 8367 38429 63441846
Blood calcium decreased 1130.53 38.05 322 8425 26129 63454146
Balance disorder 1006.93 38.05 392 8355 84030 63396245
Depressed level of consciousness 893.67 38.05 331 8416 61747 63418528
Mobility decreased 716.68 38.05 343 8404 120816 63359459
Hypotension 692.31 38.05 441 8306 272163 63208112
Constipation 659.43 38.05 399 8348 224544 63255731
Fall 573.40 38.05 453 8294 391881 63088394
Toxicity to various agents 548.33 38.05 368 8379 246882 63233393
Multiple drug therapy 176.07 38.05 49 8698 3597 63476678
Pain 152.91 38.05 322 8425 740306 62739969
Endometriosis 93.43 38.05 33 8714 5287 63474988
Drug specific antibody 92.74 38.05 27 8720 2328 63477947
Diabetes mellitus inadequate control 74.48 38.05 38 8709 15088 63465187
Blood pressure inadequately controlled 58.51 38.05 23 8724 4955 63475320
Fatigue 58.19 38.05 25 8722 888003 62592272
Hypocoagulable state 57.25 38.05 16 8731 1191 63479084
Headache 51.76 38.05 12 8735 633229 62847046
Exercise tolerance decreased 49.55 38.05 21 8726 5476 63474799
Cardiogenic shock 44.93 38.05 29 8718 17903 63462372
Oesophageal food impaction 42.40 38.05 9 8738 208 63480067
Nausea 41.90 38.05 34 8713 854437 62625838
Oesophageal achalasia 40.14 38.05 10 8737 476 63479799
Diarrhoea 38.22 38.05 26 8721 715340 62764935

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatic carcinoma metastatic 71.12 23.45 19 1976 2921 34952015
Linear IgA disease 41.65 23.45 11 1984 1615 34953321
Interstitial lung disease 38.59 23.45 31 1964 65251 34889685
Pancreatitis acute 34.69 23.45 21 1974 28120 34926816
Ischaemic stroke 34.41 23.45 18 1977 18232 34936704
Pulmonary fibrosis 34.27 23.45 18 1977 18378 34936558
Sudden death 31.56 23.45 16 1979 15185 34939751
Cerebral haematoma 30.35 23.45 11 1984 4604 34950332
Bradycardia 25.18 23.45 26 1969 75392 34879544
Subdural haematoma 24.54 23.45 15 1980 20406 34934530
Eosinophilia 23.46 23.45 16 1979 26206 34928730

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 1358.15 27.40 333 10456 15336 79718263
Creatinine renal clearance decreased 1284.58 27.40 331 10458 18671 79714928
Cognitive disorder 1221.22 27.40 428 10361 69498 79664101
Orthostatic hypotension 1212.24 27.40 403 10386 55761 79677838
Sedation 1166.35 27.40 384 10405 51511 79682088
Blood calcium decreased 1128.76 27.40 334 10455 31485 79702114
Balance disorder 976.20 27.40 399 10390 98458 79635141
Depressed level of consciousness 799.03 27.40 344 10445 96308 79637291
Mobility decreased 743.30 27.40 351 10438 121824 79611775
Constipation 606.84 27.40 410 10379 282640 79450959
Hypotension 589.48 27.40 480 10309 439837 79293762
Fall 530.53 27.40 472 10317 487157 79246442
Toxicity to various agents 400.71 27.40 379 10410 421161 79312438
Pain 190.78 27.40 340 10449 703462 79030137
Multiple drug therapy 167.02 27.40 48 10741 4030 79729569
Endometriosis 101.87 27.40 32 10757 3636 79729963
Drug specific antibody 85.98 27.40 26 10763 2602 79730997
Diabetes mellitus inadequate control 60.86 27.40 39 10750 24225 79709374
Pancreatic carcinoma metastatic 54.00 27.40 20 10769 3733 79729866
Blood pressure inadequately controlled 50.81 27.40 22 10767 6155 79727444
Hypocoagulable state 48.36 27.40 16 10773 2143 79731456
Fatigue 46.40 27.40 35 10754 929692 78803907
Pneumonia 44.37 27.40 17 10772 660229 79073370
Bradycardia 43.57 27.40 71 10718 135486 79598113
Cerebral haematoma 42.52 27.40 21 10768 7921 79725678
Headache 40.45 27.40 19 10770 653753 79079846
Oesophageal food impaction 37.20 27.40 9 10780 386 79733213
Exercise tolerance decreased 37.06 27.40 20 10769 9051 79724548
Oesophageal achalasia 35.45 27.40 10 10779 784 79732815
Morbid thoughts 35.35 27.40 10 10779 792 79732807
Nausea 35.19 27.40 47 10742 957149 78776450
Cor pulmonale acute 32.14 27.40 9 10780 687 79732912
Diarrhoea 30.57 27.40 45 10744 880444 78853155
Death 29.93 27.40 20 10769 566494 79167105

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AB04 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, selective
ATC C07BB04 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, selective, and thiazides
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:35530 beta-adrenergic blockers
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:38070 antiarrhythmic agent
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058671 Adrenergic beta-1 Receptor Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ventricular premature beats indication 17338001
Hypertensive disorder indication 38341003 DOID:10763
Anxiety off-label use 48694002
Thyrotoxicosis off-label use 90739004 DOID:7997
Angina pectoris off-label use 194828000
Mitral valve prolapse off-label use 409712001
Myocardial Reinfarction Prevention off-label use
Psoriasis contraindication 9014002 DOID:8893
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Sick sinus syndrome contraindication 36083008 DOID:13884
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
Diabetes mellitus contraindication 73211009 DOID:9351
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Pheochromocytoma contraindication 302835009
Severe chronic obstructive pulmonary disease contraindication 313299006
Peripheral arterial occlusive disease contraindication 399957001
Peripheral vascular disease contraindication 400047006
Acute exacerbation of asthma contraindication 708038006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR Ki 6.40 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 5 CHEMBL

External reference:

IDSource
4018063 VUID
N0000179521 NUI
D00597 KEGG_DRUG
34381-68-5 SECONDARY_CAS_RN
142130 RXNORM
C0000946 UMLSCUI
CHEBI:2379 CHEBI
CHEMBL642 ChEMBL_ID
CHEMBL1200813 ChEMBL_ID
DB01193 DRUGBANK_ID
D000070 MESH_DESCRIPTOR_UI
1978 PUBCHEM_CID
7107 IUPHAR_LIGAND_ID
3295 INN_ID
67P356D8GH UNII
3597005 SNOMEDCT_US
372815001 SNOMEDCT_US
68088000 SNOMEDCT_US
4018063 VANDF
4019592 VANDF
4118 MMSL
64 MMSL
d00128 MMSL
001858 NDDF
004742 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-630 CAPSULE 200 mg ORAL ANDA 21 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-631 CAPSULE 400 mg ORAL ANDA 21 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-010 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-050 CAPSULE 200 mg ORAL ANDA 13 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-666 CAPSULE 200 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51407-667 CAPSULE 400 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53746-669 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53746-669 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53746-670 CAPSULE 400 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53746-670 CAPSULE 400 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-4216 CAPSULE 400 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5520 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-255 CAPSULE 200 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-255 CAPSULE 200 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-256 CAPSULE 400 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 62559-256 CAPSULE 400 mg ORAL ANDA 23 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-669 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-669 CAPSULE 200 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-670 CAPSULE 400 mg ORAL ANDA 14 sections
Acebutolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 65162-670 CAPSULE 400 mg ORAL ANDA 14 sections
SECTRAL HUMAN PRESCRIPTION DRUG LABEL 1 67857-700 CAPSULE 200 mg ORAL NDA 26 sections
SECTRAL HUMAN PRESCRIPTION DRUG LABEL 1 67857-701 CAPSULE 400 mg ORAL NDA 26 sections